rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics

NCT02356419 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Renal Failure

Interventions

DRUG: Recombinant erythropoietin stimulating protein

Sponsor

Shenyang Sunshine Pharmaceutical Co., LTD.